Dropping in after the Q1 fins. Since we know that the company reads this board, I have a few questions that might help the current/potential investors better understand and evaluate the Company.
First off, congrats to SOHM on continued revenue growth and profitability. That said, it would be interesting to learn more about the following:
1) Any guidance re: the March 2021 and August 2021 customer mandates? Reviewing year-over-year revenues, it doesn't appear that these have come to fruition, or if so, had only a moderate impact on revenue.
2) Any guidance re: Brainwise Omega? Your November 2021 PR stated that "the first purchase order valued at $750,000 has been received", and your March 4 2022 Tweet stated that "SOHM is pleased to announce that the second shipment of Brainwise-Omega 3 formula is set to dispatch to Ghana, Africa by March-end 2022." Given that this indicated two orders were shipped by the end of 2022Q1, why are we not seeing a larger reflection on revenue? Did the $750,000 number reflect SOHM's projected revenue from this sale, or was it the projected retail price?
3) Any updates on the acquisition initially announced in April 2021?
4) Is there a reason for the negative AR on the balance sheet?
5) Section 7 of the disclosure requires the reporting of "any person or entity owning 5% of more of any class of the issuer’s securities". Section 3 states that "Shailesh Shah transferred all of his shares of Series A Preferred stock (51 shares)". Should these transferred preferred shares be reported?
Some of these may be backward looking to some degree, but learning more about their outcomes will help current/future investors better evaluate forward looking statements as they occur.
